← Back to Clinical Trials
Recruiting NCT07155057

NCT07155057 Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07155057
Status Recruiting
Phase
Sponsor Vance Thompson Vision
Condition Dry Eye Disease (DED)
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-09-03
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-09-03 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To review how patients report using a hyaluronate crosslinked canalicular gel placed before cataract surgery

Eligibility Criteria

Inclusion Criteria: * Be willing and able to understand and sign the informed consent form (ICF) * Men or non-pregnant women age 22 or older * Clear intraocular media other than cataract * Diagnosis of dry eye disease (OSDI score ≥ 13) * Non-invasive Tear break up time ≤ 10 seconds in at least one eye * Willing and able to comply with all study related visits and procedures * In the opinion of the investigator, patients who are appropriate for advanced technology lens implants Exclusion Criteria: * History of punctal cautery * Lacrimal anatomy (e.g., nasolacrimal duct obstruction) that per investigator suggests that the patient would not be a good candidate for lacrimal occlusion or patients for whom lacrimal occlusion would increase risk

Contact & Investigator

Central Contact

Tiffany Facile

✉ tiffany.facile@vancethompsonvision.com

📞 605-371-7075

Principal Investigator

Kayla Karpuk, OD

PRINCIPAL INVESTIGATOR

Vance Thompson Vision Clinic Prof. LLC

Frequently Asked Questions

Who can join the NCT07155057 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, studying Dry Eye Disease (DED). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07155057 currently recruiting?

Yes, NCT07155057 is actively recruiting participants. Contact the research team at tiffany.facile@vancethompsonvision.com for enrollment information.

Where is the NCT07155057 trial being conducted?

This trial is being conducted at Sioux Falls, United States.

Who is sponsoring the NCT07155057 clinical trial?

NCT07155057 is sponsored by Vance Thompson Vision. The principal investigator is Kayla Karpuk, OD at Vance Thompson Vision Clinic Prof. LLC. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology